TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9470078

Group type: EXPERIMENTAL
Intervention: Volume group received a rapid (10‐min) 6 ml/kg infusion of a 6% hydroxyethyl starch preparation during mechanical ventilation (MV).
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group did not receive volume loading.
Number of subjects: 18
Study: 7887106

Group type: EXPERIMENTAL
Intervention: HF+TEA group (high-dose fentanyl + TEA with 10 ml bupivacaine 5 mg.ml‐1 followed by 4 ml every hour)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LF+TEA group (low-dose fentanyl + TEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HF group (high-dose fentanyl 55 micrograms.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural groups (HF+TEA and LF+TEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HF group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural group patients
Number of subjects: 30
Study: 2974978

Group type: EXPERIMENTAL
Intervention: 0.5 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incremental doses of calcitonin after 3 injections if blood calcium level had not been reduced by more than 0.4 mmoles/l
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study: 30590503

Group type: EXPERIMENTAL
Intervention: Normothermic iliac perfusion (group A)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (group B)
Number of subjects: 190
Study: 28461129

Group type: EXPERIMENTAL
Intervention: Extensible lumbar belt
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-extensible lumbar belt
Number of subjects: 57

Group type: COMPARATOR
Intervention: No lumbar belt
Number of subjects: 57
Study: 25599346

Group type: EXPERIMENTAL
Intervention: Combination therapy with voriconazole and anidulafungin
Number of subjects: 454

Group type: COMPARATOR
Intervention: Voriconazole monotherapy
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Combination therapy with voriconazole and anidulafungin (post hoc analysis)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Voriconazole monotherapy (post hoc analysis)
Number of subjects: 454
Study: 24622415

Group type: EXPERIMENTAL
Intervention: IL2 at 0.33 MIU/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IL2 at 1 MIU/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IL2 at 3 MIU/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22107691

Group type: EXPERIMENTAL
Intervention: Cinacalcet-based regimen
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional therapy (vitamin D and phosphate binders)
Number of subjects: 82
Study: 19093921

Group type: EXPERIMENTAL
Intervention: Low to moderate alcohol intake (drinkers)
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Nondrinkers
Number of subjects: 5804
Study: 15959459

Group type: EXPERIMENTAL
Intervention: 12% oxygen (hypoxia) for 18 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: 21% oxygen (normoxia) for 18 hours
Number of subjects: 22
Study: 12542601

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole (u.i.d) for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg rebamipide (t.i.d) for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine (b.i.d) for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 75 mg roxatidine (b.i.d) for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without medication)
Number of subjects: 30
Study: 10632645

Group type: EXPERIMENTAL
Intervention: BTC regimen (colloidal bismuth subcitrate 220 mg b.d., tinidazole 500 mg b.d., clarithromycin 250 mg b.d.)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: OBTC regimen (omeprazole 20 mg daily for 4 weeks with BTC regimen during the first week)
Number of subjects: 115
Study: 9505989

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Imipramine (75 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) and Imipramine (75 mg) (combined)
Number of subjects: 9
Study: 8453092

Group type: EXPERIMENTAL
Intervention: MP/IFN (melphalan/prednisone with natural interferon-alpha)
Number of subjects: 335

Group type: COMPARATOR
Intervention: MP (melphalan/prednisone)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: MP/IFN
Number of subjects: 335

Group type: COMPARATOR
Intervention: MP
Number of subjects: 335
Study: 3090978

Group type: EXPERIMENTAL
Intervention: Elemental diet administered by needle‐catheter jejunostomy (NCJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 20
Study: 29463586

Group type: EXPERIMENTAL
Intervention: Engager intervention plus standard care
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 280
Study: 27164841

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 172

Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 172

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 172
Study: 24560331

Group type: EXPERIMENTAL
Intervention: 12-week rehabilitation training program (RT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard follow up (CON)
Number of subjects: 45
Study: 21935753

Group type: EXPERIMENTAL
Intervention: Seeing a physician in the past year
Number of subjects: 4021

Group type: EXPERIMENTAL
Intervention: Being asked about drinking by a physician
Number of subjects: 4021

Group type: EXPERIMENTAL
Intervention: Advice about safe drinking levels
Number of subjects: 4021

Group type: EXPERIMENTAL
Intervention: Exceeding low-risk drinking guidelines (ages 18-25)
Number of subjects: 4021

Group type: EXPERIMENTAL
Intervention: Exceeding low-risk drinking guidelines (ages 26-39)
Number of subjects: 4021

Group type: EXPERIMENTAL
Intervention: Being asked about drinking (ages 18-25)
Number of subjects: 4021

Group type: EXPERIMENTAL
Intervention: Being asked about drinking (ages 26-39)
Number of subjects: 4021
Study: 20532651

Group type: EXPERIMENTAL
Intervention: Veterans
Number of subjects: 360

Group type: COMPARATOR
Intervention: Non-veterans
Number of subjects: 360
Study: 18657739

Group type: EXPERIMENTAL
Intervention: Intra-articular sufentanil (5 microg) with ropivacaine (100 mg) and clonidine (1 microg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group with ropivacaine (100 mg) and clonidine (1 microg/kg) without sufentanil
Number of subjects: 120
Study: 16308129

Group type: EXPERIMENTAL
Intervention: Regular follow-up by the nutrition team (weekly in hospital, monthly after discharge)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No specific nutrition team input (control group)
Number of subjects: 112
Study: 12549816

Group type: EXPERIMENTAL
Intervention: Monthly mail-based educational intervention to patients and prescribers regarding medication adherence (intervention group)
Number of subjects: 9564

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 9564

Group type: EXPERIMENTAL
Intervention: Monthly mail-based educational intervention
Number of subjects: 9564

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 9564
Study: 10367596

Group type: EXPERIMENTAL
Intervention: L-DOPA (0.10 g, p.o., t.i.d., for 1 day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: L-DOPA (0.25 g, p.o., t.i.d., for 2 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: L-DOPA (both doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8754370

Group type: EXPERIMENTAL
Intervention: Children with goitre
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control group (children without goitre)
Number of subjects: 294
Study: 8389333

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 3430499

Group type: EXPERIMENTAL
Intervention: Cefonicid (1-g intravenous dose after cord clamping)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cefoxitin (2-g intravenous dose after cord clamping and at 6, 12, and 18 hours postpartum)
Number of subjects: 139
Study: 30630805

Group type: EXPERIMENTAL
Intervention: Mesalazine + Bifid Triple Viable Capsules
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mesalazine (Control)
Number of subjects: 120
Study: 26197940

Group type: EXPERIMENTAL
Intervention: Short-term oral immunotherapy (OIT) with Cry j1-galactomannan conjugate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no OIT)
Number of subjects: 47
Study: 28509487

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lozartan potassium
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination of perindopril and lozartan potassium
Number of subjects: 78

Group type: COMPARATOR
Intervention: Long-term monotherapy with perindopril
Number of subjects: 78
Study: 23684755

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 466

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 466
Study: 21131668

Group type: EXPERIMENTAL
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17.4 mg/24 h rivastigmine patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 to 12 mg/d rivastigmine capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine-treated groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18427220

Group type: EXPERIMENTAL
Intervention: Single-point injection of botulinum toxin A into one site
Number of subjects: 17

Group type: COMPARATOR
Intervention: Multiple-points injection of botulinum toxin A into two sites on both heads of the gastrocnemius
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Single-point injection of botulinum toxin A
Number of subjects: 17
Study: 16583205

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12791614

Group type: EXPERIMENTAL
Intervention: Original wheat germ containing 328 mg phytosterols
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phytosterol-free wheat germ
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wheat germ with extracted-and-reconstituted phytosterol
Number of subjects: 10
Study: 10592853

Group type: EXPERIMENTAL
Intervention: FemCap with 2% nonoxynol-9 spermicide
Number of subjects: 841

Group type: COMPARATOR
Intervention: Ortho All-Flex diaphragm with 2% nonoxynol-9 spermicide
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: FemCap
Number of subjects: 841

Group type: COMPARATOR
Intervention: FemCap and Ortho All-Flex diaphragm
Number of subjects: 841
Study: 7697242

Group type: EXPERIMENTAL
Intervention: BiPAP ventilatory assistance using a non‐rebreather valve and volume cycled ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: BiPAP ventilatory assistance using a standard exhalation device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of a new plateau exhalation device or a non‐rebreather valve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing exhalation devices
Number of subjects: 0
Study: 2666237

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 131
Study: 338401

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 127

Group type: COMPARATOR
Intervention: Viloxazine
Number of subjects: 127
Study: 30637889

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) treatment regimen (2 mA current, 30 min sessions, twice a week for up to 24 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) treatment
Number of subjects: 24
Study: 28816893

Group type: EXPERIMENTAL
Intervention: ON-Q Pain Relief System pump (bupivacaine HCl)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Exparel (liposomal bupivacaine)
Number of subjects: 200
Study: 25771249

Group type: EXPERIMENTAL
Intervention: 2 year multidomain intervention (diet, exercise, cognitive training, vascular risk monitoring)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: General health advice (control group)
Number of subjects: 1260
Study: 23732950

Group type: EXPERIMENTAL
Intervention: Visual stimulation at frequencies below 0.12 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Visual stimulation at frequencies between 0.12 and 0.25 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Visual stimulation at frequencies above 0.5 Hz
Number of subjects: 12
Study: 21345487

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (10 days of omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard therapy (7 days of omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 440
Study: 19321567

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (2.5 g with each main meal for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo supplementation (2.5 g with each main meal for 3 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 30
Study: 17348758

Group type: EXPERIMENTAL
Intervention: Group music therapy carried out once weekly for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmusic therapy group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group music therapy
Number of subjects: 0
Study: 15353506

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Routine abciximab administration
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Reperfusion modality (stents or glycoprotein IIb/IIIa inhibitors)
Number of subjects: 2082
Study: 11598468

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Barriers to conducting surgical randomized controlled trials
Number of subjects: 195
Study: 9415962

Group type: EXPERIMENTAL
Intervention: Coloured overlays (10 coloured plastic sheets and 19 pairwise combinations)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Chosen coloured overlay
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Chosen overlay
Number of subjects: 152
Study: 7876011

Group type: EXPERIMENTAL
Intervention: Prophylactic digitalization with digoxin postoperatively
Number of subjects: 65

Group type: COMPARATOR
Intervention: No prophylactic digitalization (control group)
Number of subjects: 65
Study: 2907314

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 18
Study: 31504982

Group type: EXPERIMENTAL
Intervention: General recommendations of good oral hygiene including teeth brushing, daily antiseptic mouthwash, and twice a year scaling.
Number of subjects: 472

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: General recommendations of good oral hygiene.
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Patients with baseline periodontal disease who became negative for one red complex bacterium.
Number of subjects: 472
Study: 29621986

Group type: EXPERIMENTAL
Intervention: Two-year comprehensive health intervention conducted by each workplace.
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Intervention implementation with high quality (scores higher than 4.047 or 4.151 out of 5).
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Health culture measured at 24 months.
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Physical environment quality measured at 12 and 24 months.
Number of subjects: 719
Study: 28891408

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo (two matched placebo tablets)
Number of subjects: 870
Study: 25147225

Group type: EXPERIMENTAL
Intervention: Baseline sRAGE levels
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: One interquartile range higher log10-transformed sRAGE
Number of subjects: 1218
Study: 23170931

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day plus rosuvastatin 5 mg/day (RC, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (R, n=20)
Number of subjects: 40
Study: 21950641

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg (single oral dose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice/day for 5 days followed by atorvastatin 20 mg (single oral dose) on day 4
Number of subjects: 23
Study: 18483451

Group type: EXPERIMENTAL
Intervention: Bladder training and Kegel exercises for 6-8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 16966616

Group type: EXPERIMENTAL
Intervention: Fixed brimonidine-timolol (0.2% brimonidine tartrate and 0.5% timolol maleate) twice daily
Number of subjects: 1159

Group type: COMPARATOR
Intervention: 0.2% brimonidine tartrate 3 times daily
Number of subjects: 1159

Group type: COMPARATOR
Intervention: 0.5% timolol maleate twice daily
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Fixed brimonidine-timolol
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 1159
Study: 12704946

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1.2% SLS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1.2% SLS and 4% betaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Toothpaste with 4% betaine (without SLS)
Number of subjects: 20
Study: 11131684

Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androstenedione
Number of subjects: 0
Study: 8632219

Group type: EXPERIMENTAL
Intervention: High fiber barley products (50:50 or 80:20 ratios)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Common barley and oat porridges
Number of subjects: 9
Study: 1459516

Group type: EXPERIMENTAL
Intervention: Octylonium bromide 40 mg tid for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6504572

Group type: EXPERIMENTAL
Intervention: Candidin (1:100)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PHA (2 micrograms)
Number of subjects: 37
Study: 30289478

Group type: EXPERIMENTAL
Intervention: Isavuconazole (200 mg IV TID for 2 days, then 200 mg IV OD)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Caspofungin (70 mg IV OD on day 1, then 50 mg IV OD)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 400

Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 400
Study: 29317186

Group type: EXPERIMENTAL
Intervention: Gamma bursts coupled to the trough of theta tACS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gamma bursts coupled to the peak of theta tACS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gamma tACS continuously superimposed with theta tACS
Number of subjects: 72
Study: 26516172

Group type: EXPERIMENTAL
Intervention: Repeated intracoronary application of autologous bone marrow-derived cells (BM-MNCs)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Single BM-MNC application
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Repeated BM-MNC application
Number of subjects: 297
Study: 25516158

Group type: EXPERIMENTAL
Intervention: ActWell programme (3 months focusing on body weight, physical activity, and alcohol)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ActWell programme
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 65
Study: 21947182

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled prosthetic knee joints
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mechanically controlled knee joint
Number of subjects: 41
Study: 19703938

Group type: EXPERIMENTAL
Intervention: Simulation debriefing
Number of subjects: 74

Group type: COMPARATOR
Intervention: Home study
Number of subjects: 74

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Both groups (debriefed and control)
Number of subjects: 74
Study: 16723306

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with different estrogen/progestogen profiles: EE 20 microg/desogestrel 150 microg, EE 30 microg/desogestrel 150 microg, EE 30 microg/gestodene 75 microg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUDs)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (40 age-matched diabetic women not using contraception)
Number of subjects: 113
Study: 15261219

Group type: EXPERIMENTAL
Intervention: Tourniquet release before wound closure (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tourniquet release after skin closure (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cemented group (Group A+)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non-cemented group (Group A-)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cemented group (Group B+)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non-cemented group (Group B-)
Number of subjects: 80
Study: 11513286

Group type: EXPERIMENTAL
Intervention: Case-based teaching approach with structured rating guidelines
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not prepared with case-based approach)
Number of subjects: 34
Study: 9505453

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Reporting a genital ulcer during follow up
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Having multiple sexual partners
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Having a urethral discharge
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Being single
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Widowed or married but not residing with wife
Number of subjects: 2992